GSK Arm Must Pay AstraZeneca For All Sales of Cancer Drug
A London court has ruled that a subsidiary of pharmaceutical giant GlaxoSmithKline focused on cancer treatments must pay royalties to AstraZeneca for all sales of its ovarian cancer treatment Zejula, following...To view the full article, register now.
Already a subscriber? Click here to view full article